巨噬细胞CBX4通过其SUMO E3连接酶活性增强动脉粥样硬化。

IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Zhenyu Zhao, Senping Xu, Jianying Ma, Zhaoshan Zhang, Sijia Liang, Jiawei Guo
{"title":"巨噬细胞CBX4通过其SUMO E3连接酶活性增强动脉粥样硬化。","authors":"Zhenyu Zhao, Senping Xu, Jianying Ma, Zhaoshan Zhang, Sijia Liang, Jiawei Guo","doi":"10.1007/s10557-025-07724-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Atherosclerosis (AS) is the leading cause of cardiovascular disease and mortality worldwide. Despite extensive research, there remains an urgent need for novel therapeutic strategies. By integrating genomic data from the Gene Expression Omnibus (GEO) with human atherosclerotic tissues, we identified enrichment of sumoylation pathways in AS, with chromobox 4 (CBX4), a SUMO E3 ligase, being significantly upregulated. This study aims to investigate the role of CBX4 in macrophages during atherosclerosis progression and its potential molecular mechanisms.</p><p><strong>Methods: </strong>We analyzed gene expression profiles from human atherosclerotic segments to identify differentially expressed pathways. High-fat diet (HFD)-challenged apolipoprotein E-deficient (ApoE<sup>-/-</sup>) mice were used to examine CBX4 expression in macrophages. The impact of CBX4 on atherosclerosis was assessed using macrophage-specific CBX4 knockdown and overexpression models. Mechanistically, we evaluated the interaction between CBX4 and hypoxia-inducible factor 1-alpha (HIF-1α) and its effect on sumoylation and transcriptional activity.</p><p><strong>Results: </strong>CBX4 expression was elevated in macrophages from atherosclerotic lesions of HFD-fed ApoE<sup>-/-</sup> mice. Macrophage-specific CBX4 knockdown significantly alleviated HFD-induced AS, whereas CBX4 overexpression exacerbated atherosclerotic progression. Mechanistically, CBX4 directly interacted with HIF-1α and promoted its sumoylation, leading to increased HIF-1α transcriptional activity, which may contribute to AS development.</p><p><strong>Conclusions: </strong>Our findings highlight CBX4-promoted SUMOylation of HIF-1α exacerbates AS progression. Targeting CBX4 may represent a promising therapeutic strategy for mitigating atherosclerosis progression.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Macrophage CBX4 Potentiates Atherosclerosis by its SUMO E3 Ligase Activity.\",\"authors\":\"Zhenyu Zhao, Senping Xu, Jianying Ma, Zhaoshan Zhang, Sijia Liang, Jiawei Guo\",\"doi\":\"10.1007/s10557-025-07724-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Atherosclerosis (AS) is the leading cause of cardiovascular disease and mortality worldwide. Despite extensive research, there remains an urgent need for novel therapeutic strategies. By integrating genomic data from the Gene Expression Omnibus (GEO) with human atherosclerotic tissues, we identified enrichment of sumoylation pathways in AS, with chromobox 4 (CBX4), a SUMO E3 ligase, being significantly upregulated. This study aims to investigate the role of CBX4 in macrophages during atherosclerosis progression and its potential molecular mechanisms.</p><p><strong>Methods: </strong>We analyzed gene expression profiles from human atherosclerotic segments to identify differentially expressed pathways. High-fat diet (HFD)-challenged apolipoprotein E-deficient (ApoE<sup>-/-</sup>) mice were used to examine CBX4 expression in macrophages. The impact of CBX4 on atherosclerosis was assessed using macrophage-specific CBX4 knockdown and overexpression models. Mechanistically, we evaluated the interaction between CBX4 and hypoxia-inducible factor 1-alpha (HIF-1α) and its effect on sumoylation and transcriptional activity.</p><p><strong>Results: </strong>CBX4 expression was elevated in macrophages from atherosclerotic lesions of HFD-fed ApoE<sup>-/-</sup> mice. Macrophage-specific CBX4 knockdown significantly alleviated HFD-induced AS, whereas CBX4 overexpression exacerbated atherosclerotic progression. Mechanistically, CBX4 directly interacted with HIF-1α and promoted its sumoylation, leading to increased HIF-1α transcriptional activity, which may contribute to AS development.</p><p><strong>Conclusions: </strong>Our findings highlight CBX4-promoted SUMOylation of HIF-1α exacerbates AS progression. Targeting CBX4 may represent a promising therapeutic strategy for mitigating atherosclerosis progression.</p>\",\"PeriodicalId\":9557,\"journal\":{\"name\":\"Cardiovascular Drugs and Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-06-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Drugs and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10557-025-07724-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-025-07724-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

目的:动脉粥样硬化(AS)是全球心血管疾病和死亡的主要原因。尽管有广泛的研究,仍然迫切需要新的治疗策略。通过整合基因表达综合(GEO)与人类动脉粥样硬化组织的基因组数据,我们发现AS中SUMO E3连接酶chromobox 4 (CBX4)的SUMO酰化途径富集。本研究旨在探讨CBX4在动脉粥样硬化过程中巨噬细胞中的作用及其潜在的分子机制。方法:我们分析了人类动脉粥样硬化段的基因表达谱,以确定差异表达途径。采用高脂饮食(HFD)挑战的载脂蛋白e缺陷(ApoE-/-)小鼠检测巨噬细胞中CBX4的表达。通过巨噬细胞特异性CBX4敲低和过表达模型评估CBX4对动脉粥样硬化的影响。在机制上,我们评估了CBX4与缺氧诱导因子1- α (HIF-1α)的相互作用及其对sumo化和转录活性的影响。结果:hfd喂养的ApoE-/-小鼠动脉粥样硬化病变巨噬细胞中CBX4表达升高。巨噬细胞特异性CBX4敲低可显著减轻hfd诱导的AS,而CBX4过表达则会加剧动脉粥样硬化的进展。机制上,CBX4直接与HIF-1α相互作用并促进其sumo化,导致HIF-1α转录活性增加,这可能有助于AS的发展。结论:我们的研究结果强调cbx4促进的HIF-1α summoylation加剧了AS的进展。靶向CBX4可能是缓解动脉粥样硬化进展的一种有希望的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Macrophage CBX4 Potentiates Atherosclerosis by its SUMO E3 Ligase Activity.

Purpose: Atherosclerosis (AS) is the leading cause of cardiovascular disease and mortality worldwide. Despite extensive research, there remains an urgent need for novel therapeutic strategies. By integrating genomic data from the Gene Expression Omnibus (GEO) with human atherosclerotic tissues, we identified enrichment of sumoylation pathways in AS, with chromobox 4 (CBX4), a SUMO E3 ligase, being significantly upregulated. This study aims to investigate the role of CBX4 in macrophages during atherosclerosis progression and its potential molecular mechanisms.

Methods: We analyzed gene expression profiles from human atherosclerotic segments to identify differentially expressed pathways. High-fat diet (HFD)-challenged apolipoprotein E-deficient (ApoE-/-) mice were used to examine CBX4 expression in macrophages. The impact of CBX4 on atherosclerosis was assessed using macrophage-specific CBX4 knockdown and overexpression models. Mechanistically, we evaluated the interaction between CBX4 and hypoxia-inducible factor 1-alpha (HIF-1α) and its effect on sumoylation and transcriptional activity.

Results: CBX4 expression was elevated in macrophages from atherosclerotic lesions of HFD-fed ApoE-/- mice. Macrophage-specific CBX4 knockdown significantly alleviated HFD-induced AS, whereas CBX4 overexpression exacerbated atherosclerotic progression. Mechanistically, CBX4 directly interacted with HIF-1α and promoted its sumoylation, leading to increased HIF-1α transcriptional activity, which may contribute to AS development.

Conclusions: Our findings highlight CBX4-promoted SUMOylation of HIF-1α exacerbates AS progression. Targeting CBX4 may represent a promising therapeutic strategy for mitigating atherosclerosis progression.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cardiovascular Drugs and Therapy
Cardiovascular Drugs and Therapy 医学-心血管系统
CiteScore
8.30
自引率
0.00%
发文量
110
审稿时长
4.5 months
期刊介绍: Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients. Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信